Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multicenter study of MK-1045 in relapsed/refractory CLL/SLL and Ph-negative B-ALL
MOH_2026-06-07_016867Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- May 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of CN201 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and B cell acute lymphoblastic leukemia (B-ALL) (2 cohorts), sponsored by Merck & Co. Primary endpoints: Safety and tolerability and Recommended dose for expansion. Planned start May 2026; status: not yet recruiting.
02
Drugs
CN201
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on MOH_2026-06-07_016867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-07_016867.